Table 1 Comparison of relapsing and non-relapsing patients

Age (years)

43.8 ± 16.6

45.6 ± 15.1

0.31

Gender (female)

77 (52.4%)

45 (42.1%)

0.07

Initial presentation: ear

53 ( 36.1%)

42 ( 39.3%)

0.34

Initial presentation: nose

36 (24.5%)

39 (36.4%)

0.03

Initial presentation: sinus

36 (24.5%)

36 (33.6%)

0.07

Initial presentation: eye

12 (8.2%)

5 (4.7%)

0.20

Initial presentation: lung

14 ( 9.5%)

2 (1.9%)

0.01

Initial presentation: kidney

0

1 (0.9%)

0.42

Initial presentation: skin

2 (1.4%)

0

0.33

Initial presentation: arthritis

0

1 (0.9%)

0.42

Initial presentation: brain vascular

90 (61.2%)

72 (67.3%)

0.19

Initial presentation: subglot

7 (4.8%)

4 (3.7%)

0.47

pseudotumor

32 (21.8%)

30 (28.0%)

0.15

Positive PR3-ANCA

108 (73.5%)

55 (51.4)

 < 0.001

Positive MPO-ANCA

12 ( 8.2%)

24 (22.4%)

0.001

eosinophilia

3 (2.0%)

7 (6.5%)

0.07

BVAS at diagnosis

17.4 ± 7.9

13.6 ± 6.7

 < 0.001

BVAS at diagnosis ≥ 8.5

130 (88.4%)

17 (11.6%)

0.01

During follow-up: nose

115 ( 78.2%)

73 (68.2%)

0.05

During follow-up: sinus

140 (95.2%)

98 (91.6%)

0.18

During follow-up: glottal

25 (17.0%)

14 (13.1%)

0.25

During follow-up: ear

101 (68.7%)

70 (65.4%)

0.34

During follow-up: lung

113 (76.9%)

82 (76.6%)

0.54

During follow-up: kidney

65 (44.2%)

52 (48.6%)

0.29

During follow-up: eye

53 (36.1%)

29 (27.1%)

0.08

During follow-up: CNS

46 (31.3%)

35 (32.7%)

0.46

During follow-up: mucosal membranes

29 (19.7%)

6 (5.6%)

0.001

During follow-up: skin

22 (15.0%)

8 (7.5%)

0.05

During follow-up: heart

9 (6.1%)

1 (0.9%)

0.03

During follow-up: GI

17 (11.6%)

2 (1.9%)

0.002

During follow-up: arthritis

16 (10.9%)

3 (2.8%)

0.01